CreatorsPublishersAdvertisers
View more in
Medical & Biotech

BioMarin Unveils News Data From Late-Stage Hemophilia A Gene Therapy Candidate

Benzinga
 2021-07-19

Cover picture for the articleBioMarin Pharmaceutical Inc (NASDAQ: BMRN) has announced new data from GENEr8-1 Phase 3 study for valoctocogene roxaparvovec, investigational gene therapy for severe hemophilia A. Data were presented at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress. Top-line one-year results from this study were previously communicated in January...

www.benzinga.com

Comments / 0

Comments / 0